Gsk and spero therapeutics announce exclusive license agreement for late-stage antibiotic asset, tebipenem hbr

The exclusive license allows gsk to commercialize tebipenem hbr in all territories, except japan and certain other asian countries

SPRO Ratings Summary

SPRO Quant Ranking